Benefits of intravenous chelation include reductions in the risk of a cardiovascular event, death from heart disease, a nonfatal stroke or a heart attack by more than 40 percent, and a 52 percent reduction in recurrent heart attacks for diabetes patients, according to the National Center for Complementary and Integrative Health. The NCCIH and the National Heart, Lung, and Blood Institute sponsored the Trial to Assess Chelation Therapy, a large-scale study that produced the results they began reporting in 2013.
The TACT study results showed that taking high doses of vitamins and minerals with the chelation therapy produces the most significant decrease in the risk of cardiovascular events, notes the NCCIH. Chelation, a chemical process that uses a substance to bind and hold metals or minerals tightly, rids the body of excess or toxic metals such as lead or iron. Health care providers usually administer a solution of a manufactured amino acid, known as disodium ethylene diamine tetra-acetic acid, in a series of intravenous infusions. Health care professionals may give their patients 30 or more infusions of several hours each per week over the course of the treatment.
Study participants who did not have diabetes did not experience any significant EDTA benefits, reports the NCCIH. Physicians use chelation therapy in conventional medicine; however, as of 2015, the U.S. Food and Drug Administration has not approved the therapy as a complementary heart disease treatment.